← Human Trials & Peer-Reviewed Studies
High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).
Plain-language guide to PMID 41423505 (2026): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 41423505
- Journal
- British journal of cancer
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Nair-Shalliker V et al. (22 authors)
- DOI
- 10.1038/s41416-025-03278-w
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
ProsD is a phase-II double-blinded randomized trial of newly diagnosed, low-intermediate risk PC cases, aged between 50 and 80 years and on AS.
Primary and secondary endpoints were active therapy-free (ATFS) and progression-free (PFS) survival, respectively.
Blood samples were analysed for vitamin D metabolites and cytokinesis-block micronucleus cytome (CBMN) markers for lymphocytic genome damage.
What Was Measured
PubMed files the paper under topics including Prostatic Neoplasms, Disease Progression, Vitamin D, Dietary Supplements and Cholecalciferol.
Author keywords: CBMN, Calcidiol, Calcitriol, Genome damage, Prostate cancer and Supplementation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2026 (British journal of cancer), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.